^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ProTmune (FT1050+FT4145 programmed mPB)

    i
    Associations
    News

    Trials

    Company:
    Fate Therap
    Drug class:
    Immunomodulator
    Related drugs:
    Associations
    News

    Trials

    Apply
    Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies (NCT02743351)
    Phase 1/2
    Fate Therapeutics
    Completed
    Last update posted :
    02/07/2023
    Initiation :
    12/20/2016
    Primary completion :
    12/04/2020
    Completion :
    11/05/2021
    HLA-DRB1 • HLA-B • HLA-C
    |
    cyclophosphamide • ProTmune (FT1050+FT4145 programmed mPB)